• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bio-Path Holdings Inc.

    10/28/24 4:35:03 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTH alert in real time by email
    DEFA14A 1 tmb-20241025xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ​

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    ​

    ​

    Bio-Path Holdings, Inc.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ​

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​


    GRAPHIC

    1. To elect five directors, each to serve until the 2025 Annual Meeting of Stockholders or until their successors have been duly elected and qualified; Peter H. Nielsen Heath W. Cleaver Paul D. Aubert Aline B. Sherwood Douglas P. Morris 2. To ratify and approve the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; 3. To approve an amendment to the Company’s 2022 Stock Incentive Plan to increase the number of shares of common stock that may be issued under the plan by 1,200,000 shares for a total 1,265,000 shares; 4. To approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share, at a ratio of up to 1-for-30, to be determined by the Board; 5. To approve the issuance of more than 20% of our common stock pursuant to the Private Placement and Nasdaq Listing Rule 5635(d); 6. To approve an adjournment of the Annual Meeting to a later date or dates, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Four. THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF DIRECTORS AND "FOR" PROPOSAL 2 THRU 6. NOMINEES: This communication is not a form for voting and presents only an overview of the more complete proxy materials that contain important information and are available to you on the Internet or by mail. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 11/29/2024. Please visit http://www.astproxyportal.com/ast/27797/, where the following materials are available for view: • Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10-K • Directions to attend the Annual Meeting and vote in person TO REQUEST MATERIAL: TELEPHONE: 888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers) E-MAIL: [email protected] WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the meeting date. IN PERSON: You may vote your shares in person by attending the Annual Meeting. MAIL: You may request a card by following the instructions above. COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER JOHN SMITH 1234 MAIN STREET APT. 203 NEW YORK, NY 10038 Please note that you cannot use this notice to vote by mail. Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting of BIO-PATH HOLDINGS, INC. To Be Held On: December 12, 2024 at 4:00 p.m. Central Standard Time Offices of Winstead PC, 24 Waterway Avenue, Suite 500, The Woodlands, Texas 77380

    Get the next $BPTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sherwood Aline

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:14:31 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Aubert Paul

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:10:56 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cleaver Heath

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Bio-Path

    Roth Capital initiated coverage of Bio-Path with a rating of Buy

    3/11/21 7:29:52 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH Capital initiated coverage on Bio-Path with a new price target

    ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00

    3/11/21 7:25:18 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Investor Forum: Now Available for Online Viewing

    NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

    6/13/25 8:35:00 AM ET
    $ATNM
    $BPTH
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Life Sciences Investor Forum Agenda Announced for June 11th-12th

    NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

    6/10/25 2:38:09 PM ET
    $ATNM
    $BPTH
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

    HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path's website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a

    6/9/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    SEC Filings

    View All

    SEC Form 10-Q filed by Bio-Path Holdings Inc.

    10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    1/13/26 11:47:25 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Bio-Path Holdings Inc.

    NT 10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    11/17/25 3:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    11/14/25 12:10:42 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

    HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications

    4/6/22 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/13/24 11:15:11 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/6/24 4:52:04 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bio-Path Holdings Inc.

    SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)

    4/3/24 5:44:32 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Financials

    Live finance-specific insights

    View All

    Bio-Path Holdings Provides Clinical and Operational Update

    HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

    6/3/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

    HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

    5/22/25 4:30:00 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Reports Full Year 2024 Financial Results

    HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

    3/28/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care